A critical review of which children with acute myeloid leukaemia need stem cell procedures

British Journal of Haematology

Volumn 166, Issue 1, 2014, Pages 23-33

  Hasle, Henrik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Acute myeloid leukaemia; Chemotherapy; Children; Haematopoietic stem cell transplantation; Late effects

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLT3 LIGAND; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOGENETICS; DISEASE FREE SURVIVAL; DONOR SELECTION; FLOW CYTOMETRY; FLT3 GENE; GENE MUTATION; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LONG TERM CARE; MINIMAL RESIDUAL DISEASE; MYELOABLATIVE CONDITIONING; NPM1 GENE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE; UNRELATED DONORS; WHOLE BODY RADIATION;

ACUTE MYELOID LEUKAEMIA; CHEMOTHERAPY; CHILDREN; HAEMATOPOIETIC STEM CELL TRANSPLANTATION; LATE-EFFECTS;

ANTINEOPLASTIC AGENTS; CHILD; CHROMOSOME ABERRATIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; PATIENT SELECTION; PROGNOSIS; TISSUE DONORS;

EID: 84902311742     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12900     Document Type: Article

References (100)

1. Abrahamsson, J., Clausen, N., Gustafsson, G., Hovi, L., Jonmundsson, G., Zeller, B., Forestier, E., Heldrup, J. & Hasle, H. (2007) Improved outcome after relapse in children with acute myeloid leukaemia. British Journal of Haematology, 136, 229-236.
2. Abrahamsson, J., Forestier, E., Heldrup, J., Jahnukainen, K., Jonsson, O.G., Lausen, B., Palle, J., Zeller, B. & Hasle, H. (2011) Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. Journal of Clinical Oncology, 29, 310-315.
3. Armenian, S.H., Sun, C.L., Kawashima, T., Arora, M., Leisenring, W., Sklar, C.A., Baker, K.S., Francisco, L., Teh, J.B., Mills, G., Wong, F.L., Rosenthal, J., Diller, L.R., Hudson, M.M., Oeffinger, K.C., Forman, S.J., Robison, L.L. & Bhatia, S. (2011) Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood, 118, 1413-1420.
4. Bajwa, R., Skeens, M., Garee, A., Miao, Y., Soni, S., Pietryga, D., Gross, T. & Termuhlen, A. (2012) Metabolic syndrome and endocrine dysfunctions after HSCT in children. Pediatric Transplantation, 16, 872-878.
5. Bajwa, R., Schechter, T., Soni, S., Gassas, A., Doyle, J., Sisler, I., Godder, K., Tatman, D., Rumelhart, S., Domm, J., Miao, Y. & Frangoul, H. (2013) Outcome of children who experience disease relapse following allogeneic hematopoietic SCT for hematologic malignancies. Bone Marrow Transplantation, 48, 661-665.
6. Balgobind, B.V., Raimondi, S.C., Harbott, J., Zimmermann, M., Alonzo, T.A., Auvrignon, A., Beverloo, H.B., Chang, M., Creutzig, U., Dworzak, M.N., Forestier, E., Gibson, B., Hasle, H., Harrison, C.J., Heerema, N.A., Kaspers, G.J., Leszl, A., Litvinko, N., Nigro, L.L., Morimoto, A., Perot, C., Pieters, R., Reinhardt, D., Rubnitz, J.E., Smith, F.O., Stary, J., Stasevich, I., Strehl, S., Taga, T., Tomizawa, D., Webb, D., Zemanova, Z., Zwaan, C.M. & van den Heuvel-Eibrink, M.M. (2009) Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood, 114, 2489-2496.
7. Ballen, K.K., Gluckman, E. & Broxmeyer, H.E. (2013) Umbilical cord blood transplantation: the first 25 years and beyond. Blood, 122, 491-498.
8. Beier, R., Albert, M.H., Bader, P., Borkhardt, A., Creutzig, U., Eyrich, M., Ehlert, K., Gruhn, B., Greil, J., Handgretinger, R., Holter, W., Klingebiel, T., Kremens, B., Lang, P., Mauz-Korholz, C., Meisel, R., Muller, I., Peters, C., Reinhardt, D., Sedlacek, P., Schulz, A., Schuster, F.R., Schrauder, A., Strahm, B., Sykora, K.W., Wossmann, W., Zimmermann, M. & Sauer, M.G. (2013) Allo-SCT using BU, CY and melphalan for children with AML in second CR. Bone Marrow Transplantation, 48, 651-656.
9. de Berranger, E., Cousien, A., Petit, A., Peffault de Latour, R., Galambrun, C., Bertrand, Y., Salmon, A., Rialland, F., Rohrlich, P.S., Vannier, J.P., Lutz, P., Yakouben, K., Duhamel, A., Bruno, B., Michel, G. & Dalle, J.H. (2014) Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Bone Marrow Transplantation, 49, 382-388.
10. Bitan, M., He, W., Zhang, M.J., Abdel-Azim, H., Ayas, M.F., Bielorai, B., Carpenter, P.A., Cairo, M.S., Diaz, M.A., Horan, J.T., Jodele, S., Kitko, C.L., Schultz, K.R., Kletzel, M., Kasow, K.A., Lehmann, L.E., Mehta, P.A., Shah, N., Pulsipher, M.A., Prestidge, T., Seber, A., Shenoy, S., Woolfrey, A.E., Yu, L.C. & Davies, S.M. (2014) Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood, 123, 1615-1620.
11. Bresters, D., van Gils, I.C., Kollen, W.J., Ball, L.M., Oostdijk, W., van der Bom, J.G. & Egeler, R.M. (2010) High burden of late effects after haematopoietic stem cell transplantation in childhood: a single-centre study. Bone Marrow Transplantation, 45, 79-85.
12. Brunet, S., Labopin, M., Esteve, J., Cornelissen, J., Socie, G., Iori, A.P., Verdonck, L.F., Volin, L., Gratwohl, A., Sierra, J., Mohty, M. & Rocha, V. (2012) Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. Journal of Clinical Oncology, 30, 735-741.
13. Buccisano, F., Maurillo, L., Del Principe, M.I., Del Poeta, G., Sconocchia, G., Lo-Coco, F., Arcese, W., Amadori, S. & Venditti, A. (2012) Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood, 119, 332-341.
14. Bunin, N.J., Davies, S.M., Aplenc, R., Camitta, B.M., DeSantes, K.B., Goyal, R.K., Kapoor, N., Kernan, N.A., Rosenthal, J., Smith, F.O. & Eapen, M. (2008) Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. Journal of Clinical Oncology, 26, 4326-4332.
15. Burke, M.J., Wagner, J.E., Cao, Q., Ustun, C. & Verneris, M.R. (2013) Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia. Biol Blood Marrow Transplant, 19, 1021-1025.
16. Canner, J., Alonzo, T.A., Franklin, J., Freyer, D.R., Gamis, A., Gerbing, R.B., Lange, B.J., Meshinchi, S., Woods, W.G., Perentesis, J. & Horan, J. (2013) Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group. Cancer, 119, 4162-4169.
17. Cornelissen, J.J., Gratwohl, A., Schlenk, R.F., Sierra, J., Bornhauser, M., Juliusson, G., Racil, Z., Rowe, J.M., Russell, N., Mohty, M., Lowenberg, B., Socie, G., Niederwieser, D. & Ossenkoppele, G.J. (2012) The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol, 9, 579-590.
18. Creutzig, U., Zimmermann, M., Ritter, J., Reinhardt, D., Hermann, J., Henze, G., Jurgens, H., Kabisch, H., Reiter, A., Riehm, H., Gadner, H. & Schellong, G. (2005) Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukaemia, 19, 2030-2042.
19. Creutzig, U., van den Heuvel-Eibrink, M.M., Gibson, B., Dworzak, M.N., Adachi, S., de Bont, E., Harbott, J., Hasle, H., Johnston, D., Kinoshita, A., Lehrnbecher, T., Leverger, G., Mejstrikova, E., Meshinchi, S., Pession, A., Raimondi, S.C., Sung, L., Stary, J., Zwaan, C.M., Kaspers, G.J. & Reinhardt, D. (2012) Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel, on behalf of the AML Committee of the International BFM Study Group. Blood, 120, 3187-3205.
20. Creutzig, U., Zimmermann, M., Bourquin, J.P., Dworzak, M.N., Fleischhack, G., Graf, N., Klingebiel, T., Kremens, B., Lehrnbecher, T., von Neuhoff, C., Ritter, J., Sander, A., Schrauder, A., von Stackelberg, A., Stary, J. & Reinhardt, D. (2013) Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood, 122, 37-43.
21. Duval, M., Klein, J.P., He, W., Cahn, J.Y., Cairo, M., Camitta, B.M., Kamble, R., Copelan, E., de Lima, M., Gupta, V., Keating, A., Lazarus, H.M., Litzow, M.R., Marks, D.I., Maziarz, R.T., Rizzieri, D.A., Schiller, G., Schultz, K.R., Tallman, M.S. & Weisdorf, D. (2010) Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. Journal of Clinical Oncology, 28, 3730-3738.
22. Dvorak, C.C., Fisher, B.T., Sung, L., Steinbach, W.J., Nieder, M., Alexander, S. & Zaoutis, T.E. (2012) Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data. Pediatric Blood & Cancer, 59, 21-26.
23. Gibson, B.E., Wheatley, K., Hann, I.M., Stevens, R.F., Webb, D., Hills, R.K., De Graaf, S.S. & Harrison, C.J. (2005) Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukaemia, 19, 2130-2138.
24. Gibson, B.E., Webb, D.K., Howman, A.J., De Graaf, S.S., Harrison, C.J. & Wheatley, K. (2011) Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. British Journal of Haematology, 155, 366-376.
25. Goemans, B.F., Tamminga, R.Y., Corbijn, C.M., Hahlen, K. & Kaspers, G.J. (2008) Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only? Haematologica, 93, 1418-1420.
26. Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A. & Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 92, 2322-2333.
27. Grimwade, D., Hills, R.K., Moorman, A.V., Walker, H., Chatters, S., Goldstone, A.H., Wheatley, K., Harrison, C.J. & Burnett, A.K. (2010a) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood, 116, 354-365.
28. Grimwade, D., Vyas, P. & Freeman, S. (2010b) Assessment of minimal residual disease in acute myeloid leukemia. Current Opinion in Oncology, 22, 656-663.
29. Guieze, R., Renneville, A., Cayuela, J.M., Abdelali, R.B., Boissel, N., de Botton, S., Rubio, M.T., Mazingue, F., Macintyre, E.A., Cheok, M., Sigaux, F., Fenaux, P., Dombret, H. & Preudhomme, C. (2010) Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience. Leukemia, 24, 1386-1388.
30. Harrison, C.J., Hills, R.K., Moorman, A.V., Grimwade, D.J., Hann, I., Webb, D.K., Wheatley, K., de Graaf, S.S., van den Berg, E., Burnett, A.K. & Gibson, B.E. (2010) Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. Journal of Clinical Oncology, 28, 2674-2681.
31. Hasle, H., Alonzo, T.A., Auvrignon, A., Behar, C., Chang, M., Creutzig, U., Fischer, A., Forestier, E., Fynn, A., Haas, O.A., Harbott, J., Harrison, C.J., Heerema, N.A., van den Heuvel-Eibrink, M.M., Kaspers, G.J., Locatelli, F., Noellke, P., Polychronopoulou, S., Ravindranath, Y., Razzouk, B., Reinhardt, D., Savva, N.N., Stark, B., Suciu, S., Tsukimoto, I., Webb, D.K., Wojcik, D., Woods, W.G., Zimmermann, M., Niemeyer, C.M. & Raimondi, S.C. (2007) Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukaemia: an international retrospective study. Blood, 109, 4641-4647.
32. Hasle, H., Abrahamsson, J., Forestier, E., Ha, S.Y., Heldrup, J., Jahnukainen, K., Jonsson, O.G., Lausen, B., Palle, J. & Zeller, B. (2012) Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood, 120, 978-984.
33. Hollink, I.H., Zwaan, C.M., Zimmermann, M., Arentsen-Peters, T.C., Pieters, R., Cloos, J., Kaspers, G.J., de Graaf, S.S., Harbott, J., Creutzig, U., Reinhardt, D., van den Heuvel-Eibrink, M.M. & Thiede, C. (2009) Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukaemia, with emphasis on cytogenetically normal AML. Leukaemia, 23, 262-270.
34. Hollink, I.H., van den Heuvel-Eibrink, M.M., Arentsen-Peters, S.T., Pratcorona, M., Abbas, S., Kuipers, J.E., van Galen, J.F., Beverloo, H.B., Sonneveld, E., Kaspers, G.J., Trka, J., Baruchel, A., Zimmermann, M., Creutzig, U., Reinhardt, D., Pieters, R., Valk, P.J. & Zwaan, C.M. (2011) NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood, 118, 3645-3656.
35. Horan, J.T., Alonzo, T.A., Lyman, G.H., Gerbing, R.B., Lange, B.J., Ravindranath, Y., Becton, D., Smith, F.O. & Woods, W.G. (2008) Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. Journal of Clinical Oncology, 26, 5797-5801.
36. Inaba, H., Coustan-Smith, E., Cao, X., Pounds, S.B., Shurtleff, S.A., Wang, K.Y., Raimondi, S.C., Onciu, M., Jacobsen, J., Ribeiro, R.C., Dahl, G.V., Bowman, W.P., Taub, J.W., Degar, B., Leung, W., Downing, J.R., Pui, C.H., Rubnitz, J.E. & Campana, D. (2012) Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. Journal of Clinical Oncology, 30, 3625-3632.
37. Jacobsohn, D.A., Tse, W.T., Chaleff, S., Rademaker, A., Duerst, R., Olszewski, M., Huang, W., Chou, P.M. & Kletzel, M. (2009) High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival. British Journal of Haematology, 146, 669-674.
38. Johnston, D.L., Alonzo, T.A., Gerbing, R.B., Hirsch, B., Heerema, N.A., Ravindranath, Y., Woods, W.G., Lange, B.J., Gamis, A.S. & Raimondi, S.C. (2013) Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols: a report from the Children's Oncology Group. Pediatric Blood & Cancer, 60, 2073-2078.
39. Jurlander, J., Caligiuri, M.A., Ruutu, T., Baer, M.R., Strout, M.P., Oberkircher, A.R., Hoffmann, L., Ball, E.D., Frei-Lahr, D.A., Christiansen, N.P., Block, A.M., Knuutila, S., Herzig, G.P. & Bloomfield, C.D. (1996) Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood, 88, 2183-2191.
40. Kaspers, G.J. & Zwaan, C.M. (2007) Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica, 92, 1519-1532.
41. Kaspers, G.J., Zimmermann, M., Reinhardt, D., Gibson, B.E., Tamminga, R.Y., Aleinikova, O., Armendariz, H., Dworzak, M., Ha, S.Y., Hasle, H., Hovi, L., Maschan, A., Bertrand, Y., Leverger, G.G., Razzouk, B.I., Rizzari, C., Smisek, P., Smith, O., Stark, B. & Creutzig, U. (2013) Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology, 31, 599-607.
42. Kelly, M.J., Horan, J.T., Alonzo, T.A., Eapen, M., Gerbing, R.B., He, W., Lange, B.J., Parsons, S.K. & Woods, W.G. (2014) Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation. Pediatric Blood & Cancer, 61, 269-275.
43. Klusmann, J.H., Reinhardt, D., Zimmermann, M., Kremens, B., Vormoor, J., Dworzak, M., Creutzig, U. & Klingebiel, T. (2012) The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica, 97, 21-29.
44. Leahey, A.M., Teunissen, H., Friedman, D.L., Moshang, T., Lange, B.J. & Meadows, A.T. (1999) Late effects of chemotherapy compared to bone marrow transplantation in the treatment of pediatric acute myeloid leukemia and myelodysplasia. Medical and Pediatric Oncology, 32, 163-169.
45. Lee, D.H., Kwon, Y.J., Lim, J., Kim, Y., Han, K., Chung, N.G., Jeong, D.C., Cho, B. & Kim, H.K. (2009) Comparable outcomes of HLA-matched unrelated and HLA-identical sibling donor bone marrow transplantation for childhood acute myeloid leukemia in first remission. Pediatric Transplantation, 13, 210-216.
46. Leung, W., Hudson, M.M., Strickland, D.K., Phipps, S., Srivastava, D.K., Ribeiro, R.C., Rubnitz, J.E., Sandlund, J.T., Kun, L.E., Bowman, L.C., Razzouk, B.I., Mathew, P., Shearer, P., Evans, W.E. & Pui, C.H. (2000) Late effects of treatment in survivors of childhood acute myeloid leukaemia. Journal of Clinical Oncology, 18, 3273-3279.
47. Leung, W., Campana, D., Yang, J., Pei, D., Coustan-Smith, E., Gan, K., Rubnitz, J.E., Sandlund, J.T., Ribeiro, R.C., Srinivasan, A., Hartford, C., Triplett, B.M., Dallas, M., Pillai, A., Handgretinger, R., Laver, J.H. & Pui, C.H. (2011) High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood, 118, 223-230.
48. Leung, W., Pui, C.H., Coustan-Smith, E., Yang, J., Pei, D., Gan, K., Srinivasan, A., Hartford, C., Triplett, B.M., Dallas, M., Pillai, A., Shook, D., Rubnitz, J.E., Sandlund, J.T., Jeha, S., Inaba, H., Ribeiro, R.C., Handgretinger, R., Laver, J.H. & Campana, D. (2012) Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood, 120, 468-472.
49. Levine, J.E., Barrett, A.J., Zhang, M.J., Arora, M., Pulsipher, M.A., Bunin, N., Fort, J., Loberiza, F., Porter, D., Giralt, S., Drobyski, W., Wang, D., Pavletic, S., Ringden, O., Horowitz, M.M. & Collins, R. Jr (2008) Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplantation, 42, 201-205.
50. Lie, S.O., Abrahamsson, J., Clausen, N., Forestier, E., Hasle, H., Hovi, L., Jonmundsson, G., Mellander, L. & Gustafsson, G. (2003) Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. British Journal of Haematology, 122, 217-225.
51. Lie, S.O., Abrahamsson, J., Clausen, N., Forestier, E., Hasle, H., Hovi, L., Jonmundsson, G., Mellander, L., Siimes, M.A., Yssing, M., Zeller, B. & Gustafsson, G. (2005) Long-term results in children with AML: NOPHO-AML Study Group - report of three consecutive trials. Leukemia, 19, 2090-2100.
52. Liesner, R.J., Leiper, A.D., Hann, I.M. & Chessells, J.M. (1994) Late effects of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood. Journal of Clinical Oncology, 12, 916-924.
53. Locatelli, F., Vinti, L., Palumbo, G., Rossi, F., Bertaina, A., Mastronuzzi, A., Bernardo, M.E., Rutella, S., Dellabona, P., Giorgiani, G., Moretta, A. & Moretta, L. (2011) Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation. Best Pract Res Clin Haematol, 24, 339-349.
54. Loken, M.R., Alonzo, T.A., Pardo, L., Gerbing, R.B., Raimondi, S.C., Hirsch, B.A., Ho, P.A., Franklin, J., Cooper, T.M., Gamis, A.S. & Meshinchi, S. (2012) Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood, 120, 1581-1588.
55. Magenau, J., Tobai, H., Pawarode, A., Braun, T., Peres, E., Reddy, P., Kitko, C., Choi, S., Yanik, G., Frame, D., Harris, A., Erba, H., Kujawski, L., Elenitoba-Johnson, K., Sanks, J., Jones, D., Paczesny, S., Ferrara, J., Levine, J. & Mineishi, S. (2011) Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood, 118, 4258-4264.
56. Meshinchi, S., Alonzo, T.A., Stirewalt, D.L., Zwaan, M., Zimmerman, M., Reinhardt, D., Kaspers, G.J., Heerema, N.A., Gerbing, R., Lange, B.J. & Radich, J.P. (2006a) Clinical implications of FLT3 mutations in pediatric AML. Blood, 108, 3654-3661.
57. Meshinchi, S., Arceci, R.J., Sanders, J.E., Smith, F.O., Woods, W.B., Radich, J.P. & Alonzo, T.A. (2006b) Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. Blood, 108, 400; author reply 400-401.
58. Michel, G., Socie, G., Gebhard, F., Bernaudin, F., Thuret, I., Vannier, J.P., Demeocq, F., Leverger, G., Pico, J.L., Rubie, H., Mechinaud, F., Reiffers, J., Gratecos, N., Troussard, X., Jouet, J.P., Simonin, G., Gluckman, E. & Maraninchi, D. (1997) Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation-a report from the Societe Francaise de Greffe de Moelle. Journal of Clinical Oncology, 15, 2238-2246.
59. Molgaard-Hansen, L., Mottonen, M., Glosli, H., Jonmundsson, G.K., Abrahamsson, J. & Hasle, H. (2011a) Treatment-related deaths in second complete remission in childhood acute myeloid leukaemia. British Journal of Haematology, 152, 623-630.
60. Molgaard-Hansen, L., Glosli, H., Jahnukainen, K., Jarfelt, M., Jonmundsson, G.K., Malmros-Svennilson, J., Nysom, K. & Hasle, H. (2011b) Quality of health in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO-AML study. Pediatric Blood & Cancer, 57, 1222-1229.
61. Molgaard-Hansen, L., Skou, A.S., Juul, A., Glosli, H., Jahnukainen, K., Jarfelt, M., Jonmundsson, G.K., Malmros, J., Nysom, K. & Hasle, H. (2013) Pubertal development and fertility in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO-AML study. Pediatric Blood & Cancer, 60, 1988-1995.
62. Moore, J., Nivison-Smith, I., Goh, K., Ma, D., Bradstock, K., Szer, J., Durrant, S., Schwarer, A., Bardy, P., Herrmann, R. & Dodds, A. (2007) Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant, 13, 601-607.
63. Mulcahy Levy, J.M., Tello, T., Giller, R., Wilkening, G., Quinones, R., Keating, A.K. & Liu, A.K. (2013) Late effects of total body irradiation and hematopoietic stem cell transplant in children under 3 years of age. Pediatric Blood & Cancer, 60, 700-704.
64. Mulrooney, D.A., Dover, D.C., Li, S., Yasui, Y., Ness, K.K., Mertens, A.C., Neglia, J.P., Sklar, C.A., Robison, L.L. & Davies, S.M. (2008) Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study. Cancer, 112, 2071-2079.
65. Niewerth, D., Creutzig, U., Bierings, M.B. & Kaspers, G.J. (2010) A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood, 116, 2205-2214.
66. Ofran, Y. & Rowe, J.M. (2013) Genetic profiling in acute myeloid leukaemia-where are we and what is its role in patient management. British Journal of Haematology, 160, 303-320.
67. Ommen, H.B., Nyvold, C.G., Braendstrup, K., Andersen, B.L., Ommen, I.B., Hasle, H., Hokland, P. & Ostergaard, M. (2008) Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. British Journal of Haematology, 141, 782-791.
68. Ossenkoppele, G.J., van de Loosdrecht, A.A. & Schuurhuis, G.J. (2011) Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. British Journal of Haematology, 153, 421-436.
69. Paillard, C., Rochette, E., Lutz, P., Bertrand, Y., Michel, G., Bordigoni, P., Dalle, J.H., Rohrlich, P., Vannier, J.P., Perel, Y., Plantaz, D., Leverger, G., Sirvent, A., Dore, E., Isfan, F., Merlin, E., Pereira, B., Halle, P., Rabiau, N., Kanold, J. & Demeocq, F. (2013) Reduced-intensity conditioning followed by allogeneic transplantation in pediatric malignancies: a report from the Societe Francaise des Cancers de l'Enfant and the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Bone Marrow Transplantation, 48, 1401-1408.
70. Palma, J., Salas, L., Carrion, F., Sotomayor, C., Catalan, P., Paris, C., Turner, V., Jorquera, H., Handgretinger, R. & Rivera, G.K. (2012) Haploidentical stem cell transplantation for children with high-risk leukemia. Pediatric Blood & Cancer, 59, 895-901.
71. Parsons, S.K., Phipps, S., Sung, L., Baker, K.S., Pulsipher, M.A. & Ness, K.K. (2012) NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: health-related quality of life, functional and neurocognitive outcomes. Biol Blood Marrow Transplant, 18, 162-171.
72. Perel, Y., Auvrignon, A., Leblanc, T., Michel, G., Reguerre, Y., Vannier, J.P., Dalle, J.H., Gandemer, V., Schmitt, C., Mechinaud, F., Lejars, O., Piguet, C., Couillaud, G., Pautard, B., Landman-Parker, J., Thuret, I., Aladjidi, N., Baruchel, A. & Leverger, G. (2005) Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit-multicenter studies of the French LAME (Leucemie Aigue Myeloblastique Enfant) Cooperative Group. Leukemia, 19, 2082-2089.
73. Pession, A., Masetti, R., Rizzari, C., Putti, M.C., Casale, F., Fagioli, F., Luciani, M., Lo Nigro, L., Menna, G., Micalizzi, C., Santoro, N., Testi, A.M., Zecca, M., Biondi, A., Pigazzi, M., Rutella, S., Rondelli, R., Basso, G. & Locatelli, F. (2013) Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood, 122, 170-178.
74. Pratcorona, M., Brunet, S., Nomdedeu, J., Ribera, J.M., Tormo, M., Duarte, R., Escoda, L., Guardia, R., Queipo de Llano, M.P., Salamero, O., Bargay, J., Pedro, C., Marti, J.M., Torrebadell, M., Diaz-Beya, M., Camos, M., Colomer, D., Hoyos, M., Sierra, J. & Esteve, J. (2013) Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood, 121, 2734-2738.
75. Pulsipher, M.A., Skinner, R., McDonald, G.B., Hingorani, S., Armenian, S.H., Cooke, K.R., Gracia, C., Petryk, A., Bhatia, S., Bunin, N., Nieder, M.L., Dvorak, C.C., Sung, L., Sanders, J.E., Kurtzberg, J. & Baker, K.S. (2012) National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines. Biol Blood Marrow Transplant, 18, 334-347.
76. Ravindranath, Y., Yeager, A.M., Chang, M.N., Steuber, C.P., Krischer, J., Graham-Pole, J., Carroll, A., Inoue, S., Camitta, B. & Weinstein, H.J. (1996) Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. New England Journal of Medicine, 334, 1428-1434.
77. Rubnitz, J.E., Inaba, H., Dahl, G., Ribeiro, R.C., Bowman, W.P., Taub, J., Pounds, S., Razzouk, B.I., Lacayo, N.J., Cao, X., Meshinchi, S., Degar, B., Airewele, G., Raimondi, S.C., Onciu, M., Coustan-Smith, E., Downing, J.R., Leung, W., Pui, C.H. & Campana, D. (2010) Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol, 11, 543-552.
78. Sandahl, J.D., Coenen, E.A., Forestier, E., Harbott, J., Johansson, B., Kerndrup, G., Adachi, S., Auvrignon, A., Beverloo, H.B., Cayuela, J.M., Chilton, L., Fornerod, M., de Haas, V., Harrison, C.J., Inaba, H., Kaspers, G.J., Liang, D.C., Locatelli, F., Masetti, R., Perot, C., Raimondi, S., Reinhardt, K., Tomizawa, D., von Neuhoff, N., Zecca, M., Zwaan, C.M., van den Heuvel-Eibrink, M.M. & Hasle, H. (2014) t(6;9)(p22;q34)/DEK-NUP214 rearranged pediatric myeloid leukemia: an international study on 62 patients. Haematologica. PMID: 24441146.
79. Sander, A., Zimmermann, M., Dworzak, M., Fleischhack, G., von Neuhoff, C., Reinhardt, D., Kaspers, G.J. & Creutzig, U. (2010) Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia, 24, 1422-1428.
80. Savani, B.N., Mielke, S., Reddy, N., Goodman, S., Jagasia, M. & Rezvani, K. (2009) Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplantation, 44, 769-777.
81. Schlenk, R.F., Taskesen, E., van Norden, Y., Krauter, J., Ganser, A., Bullinger, L., Gaidzik, V.I., Paschka, P., Corbacioglu, A., Gohring, G., Kundgen, A., Held, G., Gotze, K., Vellenga, E., Kuball, J., Schanz, U., Passweg, J., Pabst, T., Maertens, J., Ossenkoppele, G.J., Delwel, R., Dohner, H., Cornelissen, J.J., Dohner, K. & Lowenberg, B. (2013) The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood, 122, 1576-1582.
82. Schnittger, S., Weisser, M., Schoch, C., Hiddemann, W., Haferlach, T. & Kern, W. (2003) New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11 + acute myeloid leukemia based on quantification of fusion transcripts. Blood, 102, 2746-2755.
83. Shaw, P.J., Kan, F., Woo Ahn, K., Spellman, S.R., Aljurf, M., Ayas, M., Burke, M., Cairo, M.S., Chen, A.R., Davies, S.M., Frangoul, H., Gajewski, J., Gale, R.P., Godder, K., Hale, G.A., Heemskerk, M.B., Horan, J., Kamani, N., Kasow, K.A., Chan, K.W., Lee, S.J., Leung, W.H., Lewis, V.A., Miklos, D., Oudshoorn, M., Petersdorf, E.W., Ringden, O., Sanders, J., Schultz, K.R., Seber, A., Setterholm, M., Wall, D.A., Yu, L. & Pulsipher, M.A. (2010) Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood, 116, 4007-4015.
84. Shiba, N., Ichikawa, H., Taki, T., Park, M.J., Jo, A., Mitani, S., Kobayashi, T., Shimada, A., Sotomatsu, M., Arakawa, H., Adachi, S., Tawa, A., Horibe, K., Tsuchida, M., Hanada, R., Tsukimoto, I. & Hayashi, Y. (2013) NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia. Genes Chromosomes Cancer, 52, 683-693.
85. Shinzato, A., Tabuchi, K., Atsuta, Y., Inoue, M., Inagaki, J., Yabe, H., Koh, K., Kato, K., Ohta, H., Kigasawa, H., Kitoh, T., Ogawa, A., Takahashi, Y., Sasahara, Y., Kato, S. & Adachi, S. (2013) PBSCT is associated with poorer survival and increased chronic GvHD than BMT in Japanese paediatric patients with acute leukaemia and an HLA-matched sibling donor. Pediatric Blood & Cancer, 60, 1513-1519.
86. Smith, F.O., Alonzo, T.A., Gerbing, R.B., Woods, W.G. & Arceci, R.J. (2005) Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia, 19, 2054-2062.
87. Song, K.W. & Lipton, J. (2005) Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? Bone Marrow Transplantation, 36, 183-191.
88. Staffas, A., Kanduri, M., Hovland, R., Rosenquist, R., Ommen, H.B., Abrahamsson, J., Forestier, E., Jahnukainen, K., Jonsson, O.G., Zeller, B., Palle, J., Lonnerholm, G., Hasle, H., Palmqvist, L. & Ehrencrona, H. (2011) Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood, 118, 5905-5913.
89. Steinbach, D., Wilhelm, B., Kiermaier, H.R., Creutzig, U., Schrappe, M., Zimmermann, M., Debatin, K.M., Gruhn, B., von Stackelberg, A., Jurgens, H., Strahm, B., Reinhardt, D. & Moricke, A. (2011) Long term survival in children with acute leukaemia and complications requiring mechanical ventilation. Archives of Disease in Childhood, 96, 1026-1032.
90. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon.
91. Temming, P., Qureshi, A., Hardt, J., Leiper, A.D., Levitt, G., Ancliff, P.J. & Webb, D.K. (2011) Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom. Pediatric Blood & Cancer, 56, 625-630.
92. Trka, J., Kalinova, M., Hrusak, O., Zuna, J., Krejci, O., Madzo, J., Sedlacek, P., Vavra, V., Michalova, K., Jarosova, M. & Stary, J. (2002) Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia, 16, 1381-1389.
93. Tsukimoto, I., Tawa, A., Horibe, K., Tabuchi, K., Kigasawa, H., Tsuchida, M., Yabe, H., Nakayama, H., Kudo, K., Kobayashi, R., Hamamoto, K., Imaizumi, M., Morimoto, A., Tsuchiya, S. & Hanada, R. (2009) Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. Journal of Clinical Oncology, 27, 4007-4013.
94. van der Velden, V.H., van der Sluijs-Geling, A., Gibson, B.E., te Marvelde, J.G., Hoogeveen, P.G., Hop, W.C., Wheatley, K., Bierings, M.B., Schuurhuis, G.J., de Graaf, S.S., van Wering, E.R. & van Dongen, J.J. (2010) Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia, 24, 1599-1606.
95. Walter, R.B., Buckley, S.A., Pagel, J.M., Wood, B.L., Storer, B.E., Sandmaier, B.M., Fang, M., Gyurkocza, B., Delaney, C., Radich, J.P., Estey, E.H. & Appelbaum, F.R. (2013) Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood, 122, 1813-1821.
96. Wareham, N.E., Heilmann, C., Abrahamsson, J., Forestier, E., Gustafsson, B., Ha, S.Y., Heldrup, J., Jahnukainen, K., Jonsson, O.G., Lausen, B., Palle, J., Zeller, B. & Hasle, H. (2013) Outcome of poor response paediatric AML using early SCT. European Journal of Haematology, 90, 187-194.
97. Woods, W.G., Neudorf, S., Gold, S., Sanders, J., Buckley, J.D., Barnard, D.R., Dusenbery, K., DeSwarte, J., Arthur, D.C., Lange, B.J. & Kobrinsky, N.L. (2001) A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood, 97, 56-62.
98. Xu, X.J., Feng, J.H., Tang, Y.M., Shen, H.Q., Song, H., Yang, S.L., Shi, S.W. & Xu, W.Q. (2013) Prognostic significance of flow cytometric minimal residual disease assessment after the first induction course in Chinese childhood acute myeloid leukemia. Leukemia Research, 37, 134-138.
99. Zimmerman, E.I., Turner, D.C., Buaboonnam, J., Hu, S., Orwick, S., Roberts, M.S., Janke, L.J., Ramachandran, A., Stewart, C.F., Inaba, H. & Baker, S.D. (2013) Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood, 122, 3607-3615.
100. Zwaan, C.M., Meshinchi, S., Radich, J.P., Veerman, A.J., Huismans, D.R., Munske, L., Podleschny, M., Hahlen, K., Pieters, R., Zimmermann, M., Reinhardt, D., Harbott, J., Creutzig, U., Kaspers, G.J. & Griesinger, F. (2003) FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood, 102, 2387-2394.